etoposide has been researched along with sdz psc 833 in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (34.29) | 18.2507 |
| 2000's | 17 (48.57) | 29.6817 |
| 2010's | 6 (17.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belinsky, MG; Chen, ZS; Kruh, GD; Rea, PA; Zeng, H | 1 |
| Bacsó, Z; Cianfriglia, M; Fenyvesi, F; Goda, K; Kappelmayer, J; Lustyik, G; Nagy, H; Szabó, G; Szilasi, M | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Altermatt, HJ; Donatsch, P; Hiestand, PC; Keller, RP; Laissue, JA; Zihlmann, H | 1 |
| Osann, K; Slater, L; Stupecky, M; Sweet, P; Wetzel, M | 1 |
| Bleehen, NM; Boote, DJ; Brampton, MH; Dennis, IF; Hensel, S; Laburte, C; Osborne, RJ; Smyth, JF; Twentyman, PR | 1 |
| Aran, JM; Gottesman, MM; Licht, T; Pastan, I | 1 |
| Osann, K; Slater, LM; Stupecky, M; Sweet, P | 1 |
| Andreeff, M; Consoli, U; Estey, E; Kantarjian, H; Keating, M; Kornblau, SM; Madden, T; Newman, RA; Sanchez-Williams, G; Snell, V; Tran, HT; Zhao, S | 1 |
| Iwasaki, M; Morikawa, H; Ohtawa, M; Todaka, T; Watanabe, T | 1 |
| Borg, AG; Burgess, R; Fisher, A; Grey, M; Wood, P; Yin, JA | 1 |
| Advani, R; Davis, E; Dugan, K; Greenberg, PL; Litchman, M; Lum, B; Paietta, E; Ramek, J; Rowe, JM; Saba, HI; Sikic, BI; Tallman, MS; Villena, J; Wiernik, PH | 1 |
| Advani, R; Covelli, A; Davis, E; Dugan, K; Greenberg, P; Litchman, M; Lum, B; Milligan, D; Paietta, E; Ramek, J; Rowe, JM; Saba, H; Sikic, B; Tallman, M; Villena, J; Visani, G; Wiernik, PH | 1 |
| Baer, M; Caligiuri, M; Dodge, RK; George, SL; Lee, EJ; Lemke, S; Powell, BL; Schiffer, CA; Smith, R; Szatrowski, TP | 1 |
| Ausema, B; Kamps, W; Kok, JW; Kolk, D; Nijhof, W; Sietsma, H; Veldman, RJ; Vellenga, E | 1 |
| Anderson, JE; Appelbaum, FR; Chauncey, TR; Chen, I; Godwin, JE; Head, DR; Kalaycio, ME; Kopecky, KJ; Kraut, EH; Leith, CP; Luthardt, FW; Moore, DF; Petersdorf, SH; Rankin, C; Shurafa, MS; Willman, CL | 1 |
| Beketic-Oreskovic, L; Chen, GK; Durán, GE; Mangili, A; Sikic, BI | 1 |
| Chang, J; Covelli, A; Isidori, A; Kelsey, S; Leoni, F; Litchman, M; Malagola, M; Marcus, R; Mayer, H; Milligan, D; Pfister, C; Piccaluga, PP; Powles, R; Schey, S; Visani, G | 1 |
| Cocker, HA; Kelland, LR; Pinkerton, CR; Pritchard-Jones, K; Tiffin, N | 1 |
| Osann, KE; Slater, LM; Stupecky, M; Sweet, P | 1 |
| Anastasi, J; Baer, MR; Bloomfield, CD; Caligiuri, MA; Dodge, RK; George, SL; Kolitz, JE; Larson, RA; Minderman, H; O'Loughlin, KL; Powell, BL; Schiffer, CA | 1 |
| Baer, M; Becknell, B; Bloomfield, CD; Caligiuri, MA; Crawford, J; Dodge, RK; Farag, SS; Fehniger, TA; George, SL; Larson, RA; Lee, EJ; Schiffer, CA; Silverman, LR | 1 |
| Advani, R; Bennett, JM; Chin, DL; Dewald, G; Dugan, K; Greenberg, PL; Lee, SJ; Letendre, L; Lum, B; Paietta, E; Rowe, JM; Sikic, BI; Tallman, MS | 1 |
| Allen, SL; Bloomfield, CD; Caligiuri, MA; Dodge, RK; George, SL; Hoke, E; Hurd, DD; Kolitz, JE; Larson, RA; Moore, JO; Powell, BL; Shea, TC; Vardiman, JW; Velez-Garcia, E | 1 |
| Bauer, KS; Garimella, TS; Karp, JE; Ross, DD; Tan, M; Wu, S | 1 |
| Ades, S; Gould, CJ; Jones, GK; Levy, SB; Maxfield, LF | 1 |
| Cole, B; Epel, D; Hamdoun, A; Thurber, RV | 1 |
| Berthaud, P; Dick, G; Pein, F; Pinkerton, R; Pritchard-Jones, K; Vassal, G | 1 |
| Arceci, RJ; Bernstein, M; Buck, S; Chang, MN; Dahl, GV; Kshirsagar, S; Lacayo, NJ; Lum, BL; O'Brien, MM; Ravindranath, Y; Sikic, BI; Weinstein, H | 1 |
| Allen, SL; Baer, MR; Bloomfield, CD; DeAngelo, DJ; George, SL; Hars, V; Hoke, E; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Powell, BL; Shea, TC; Stock, W; Vardiman, JW; Vij, R | 1 |
| Allen, SL; Bakan, CE; Benson, DM; Bloomfield, CD; Caligiuri, MA; Deangelo, DJ; George, SL; Hars, V; Hoke, E; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Powell, BL; Shea, TC; Stock, W; Vij, R | 1 |
| Aitken, RJ; Bromfield, EG; Lord, T; Martin, JH; Nixon, B | 1 |
15 trial(s) available for etoposide and sdz psc 833
| Article | Year |
|---|---|
Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Cyclosporins; Drug Resistance, Multiple; Etoposide; Female; Half-Life; Humans; Male; Middle Aged; Neoplasms | 1996 |
Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Drug Resistance, Neoplasm; Etoposide; Genes, MDR; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Recurrence | 1997 |
Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Cardiovascular Diseases; Cohort Studies; Cyclosporins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Recombinant Proteins; Remission Induction; Treatment Outcome | 1999 |
Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC).
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Cytarabine; Etoposide; Genes, MDR; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Prognosis; Remission Induction; Salvage Therapy | 1999 |
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia g
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged | 1999 |
A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Survival Analysis; Treatment Outcome | 2000 |
Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Cytarabine; Drug Resistance, Multiple; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone | 2001 |
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Remission Induction | 2002 |
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Topics: Acute Disease; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclosporins; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Fatigue; Gene Expression Regulation, Neoplastic; Hematologic Diseases; Humans; Immunologic Factors; Interleukin-2; Killer Cells, Natural; Leukemia, Myeloid; Life Tables; Middle Aged; Nausea; Neoplasm Proteins; NK Cell Lectin-Like Receptor Subfamily K; Receptors, Immunologic; Receptors, Natural Killer Cell; Recombinant Fusion Proteins; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Disease-Free Survival; Etoposide; Female; Genes, MDR; Humans; Logistic Models; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Myelodysplastic Syndromes; Survival Analysis; United States | 2004 |
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Logistic Models; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2004 |
A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Drug Interactions; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Leukemia; Male; Maximum Tolerated Dose; Middle Aged; Treatment Outcome | 2005 |
Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Child; Child, Preschool; Cyclosporins; Drug Resistance, Multiple; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy; Young Adult | 2010 |
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Interleukin-2; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombinant Proteins; Remission Induction; Survival Rate; Treatment Outcome | 2014 |
20 other study(ies) available for etoposide and sdz psc 833
| Article | Year |
|---|---|
Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport.
Topics: 3T3 Cells; Animals; ATP-Binding Cassette Transporters; Biological Transport; Drug Resistance, Multiple; Folic Acid; Humans; Leucovorin; Methotrexate; Mice; Multidrug Resistance-Associated Proteins; Osmolar Concentration; Polyglutamic Acid; Tritium | 2001 |
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Calcium Channel Blockers; Cyclosporine; Detergents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Humans; Ivermectin; Mice; NIH 3T3 Cells; Substrate Specificity | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity.
Topics: Adenocarcinoma; Adult; Animals; Colonic Neoplasms; Cyclosporins; Drug Administration Schedule; Drug Interactions; Drug Screening Assays, Antitumor; Etoposide; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Specific Pathogen-Free Organisms | 1992 |
Comparison of cyclosporin A, verapamil, PSC-833 and cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias.
Topics: Animals; Cell Survival; Cyclosporine; Cyclosporins; Drug Synergism; Etoposide; Glycerol; Leukemia L1210; Leukemia P388; Mice; Survival Analysis; Tumor Cells, Cultured; Verapamil | 1995 |
Chemotherapy enhancer passes first test.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clinical Trials, Phase I as Topic; Cyclosporins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Male; Neoplasms; Paclitaxel | 1995 |
Complete restoration of glucocerebrosidase deficiency in Gaucher fibroblasts using a bicistronic MDR retrovirus and a new selection strategy.
Topics: Animals; Anthracenes; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Northern; Blotting, Western; Cells, Cultured; Colchicine; Cyclosporins; DNA, Complementary; Doxorubicin; Drug Resistance, Multiple; Etoposide; Fibroblasts; Gaucher Disease; Gene Expression Regulation; Genetic Therapy; Genetic Vectors; Glucosylceramidase; Humans; Mice; Mutagenesis, Insertional; Retroviridae; Transfection; Verapamil | 1996 |
Superiority of cyclosporin A over PSC-833 in enhancement of VP-16 efficacy in murine tumors in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cyclosporine; Cyclosporins; Drug Synergism; Etoposide; Female; Immunosuppressive Agents; Leukemia L1210; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Survival Rate; Time Factors | 1997 |
Effect of SDZ PSC 833 ([3'-keto-Bmt1]-[Val2]-cyclosporin) on serum protein binding and distribution to blood cells of doxorubicin, vincristine and etoposide in vitro.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Blood Cells; Blood Proteins; Cyclosporins; Doxorubicin; Drug Interactions; Drug Resistance, Multiple; Etoposide; Humans; Mice; Mice, Inbred Strains; Protein Binding; Tissue Distribution; Vincristine | 1997 |
Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Coloring Agents; Cyclosporine; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1997 |
1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine.
Topics: Animals; Antineoplastic Agents; Cell Survival; Ceramides; Cyclosporins; Drug Synergism; Enzyme Inhibitors; Etoposide; Glucosyltransferases; Morpholines; Neuroblastoma; Paclitaxel; Tumor Cells, Cultured; Vincristine | 2000 |
MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Cyclosporins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Multidrug Resistance-Associated Proteins; Mutation; Neoplasm Proteins; Paclitaxel; Phenotype; Rhodamine 123; RNA, Messenger; Sarcoma; Tritium; Tumor Cells, Cultured; Uterine Neoplasms; Vault Ribonucleoprotein Particles; Vinblastine | 2000 |
In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Child; Cisplatin; Cyclosporins; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Indomethacin; Inhibitory Concentration 50; Piperidines; Pyridines; Quinolines; Razoxane; Rhabdomyosarcoma; RNA, Neoplasm; Staurosporine; Time Factors; Tumor Cells, Cultured; Vincristine | 2001 |
Enhancement of leukemia rejection by mice successfully treated for L1210 leukemia due to low dose compared to high dose VP-16.
Topics: Animals; Antineoplastic Agents, Phytogenic; Concanavalin A; Cyclosporine; Cyclosporins; Drug Screening Assays, Antitumor; Etoposide; Graft Rejection; Immunosuppressive Agents; Leukemia L1210; Lymphocyte Activation; Mice; Mice, Inbred DBA; Neoplasm Transplantation; Phytohemagglutinins | 2002 |
Selection of non-P-glycoprotein mediated high-level etoposide resistant cell lines by adriamycin with P-gp inhibitors.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Transporters; Blotting, Western; Cell Line, Tumor; Cell Survival; Cyclosporins; Daunorubicin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Mice; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Verapamil | 2006 |
The sea urchin embryo as a model for studying efflux transporters: roles and energy cost.
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Cyclosporins; Cytotoxins; Embryo, Nonmammalian; Energy Metabolism; Etoposide; Fluoresceins; Membrane Transport Proteins; Models, Animal; Propionates; Quinolines; Sea Urchins; Verapamil; Vinblastine | 2006 |
Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Ataxia; Child; Child, Preschool; Cohort Studies; Cyclosporins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Feasibility Studies; Female; Gastrointestinal Diseases; Humans; Infant; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local | 2007 |
Identification of a key role for permeability glycoprotein in enhancing the cellular defense mechanisms of fertilized oocytes.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; DNA Breaks, Double-Stranded; Etoposide; Female; Fertilization; Male; Mice; Mice, Inbred C57BL; Oocytes; Permeability; Topoisomerase II Inhibitors | 2016 |